Background A study published in the prestigious JAMA Oncology (The Journal of the American Medical Association) confirmed an association between maximal resection of contrast-enhanced tumor and survival in patients with…
Background The FDA granted fast track designation to Onivyde injection for the treatment of patients with Small Cell Lung Cancer, SCLC, who progressed following a first-line platinum-based regimen. The fast…
Background Women with advanced ovarian cancer have limited treatment options in the standard of care and therefore they have much better chances and hope in fighting their disease with new…
A Compassionate Drug is a new drug. So, first of all one needs to know that a Compassionate Drug is a new drug. The newest there is. This is a…
Background Gastric cancer has a new target to attack: FGFR2b. Anew drug, “Bemarituzumab”, targets FGFR2b. When Bemarituzumab was given with chemotherapy, the combination postponed the time until the disease recurred,…
Background On average, KRAS is mutated in approximately 50% of patients with colorectal cancer. Chemotherapy in combination with targeted drugs is standard of care option for patients with metastatic colorectal…
Background Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality of life, representing an unmet need for tolerable and effective therapies. About the…
Background Melanoma is a serious form of skin cancer that begins in cells known as melanocytes. Melanoma is dangerous because it can rapidly spread to other organs in the body…
Background Patients with advanced or metastatic breast cancer have very few effective treatment options. The lack of successful therapeutic strategies is reflected by a low 5-year survival. There continues to…
Background - Glioblastoma and MDNA55 The interleukin-4 receptor–targeted immunotherapeutic MDNA55 has demonstrated improved survival and disease control in patients with recurrent Glioblastoma who are treated at high dose, irrespective of…